SRR1500998
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- COAGULATION+0.400
- KRAS_SIGNALING_DN+0.399
- XENOBIOTIC_METABOLISM+0.317
- INFLAMMATORY_RESPONSE+0.240
- ESTROGEN_RESPONSE_LATE+0.239
- MYOGENESIS+0.230
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.228
- BILE_ACID_METABOLISM+0.221
- SPERMATOGENESIS+0.167
- IL6_JAK_STAT3_SIGNALING+0.164
Top 10 suppressed
- MYC_TARGETS_V1-0.582
- MYC_TARGETS_V2-0.562
- PROTEIN_SECRETION-0.517
- DNA_REPAIR-0.483
- UNFOLDED_PROTEIN_RESPONSE-0.470
- OXIDATIVE_PHOSPHORYLATION-0.453
- G2M_CHECKPOINT-0.452
- E2F_TARGETS-0.437
- MTORC1_SIGNALING-0.412
- MITOTIC_SPINDLE-0.369
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1366961 | GTEX | — | 0.959 |
| 2 | SRR1340202 | GTEX | — | 0.959 |
| 3 | SRR1099168 | GTEX | — | 0.941 |
| 4 | SRR1392725 | GTEX | — | 0.939 |
| 5 | SRR1400269 | GTEX | — | 0.934 |
| 6 | SRR1475022 | GTEX | — | 0.933 |
| 7 | SRR1352554 | GTEX | — | 0.921 |
| 8 | SRR1420215 | GTEX | — | 0.921 |
| 9 | SRR1444559 | GTEX | — | 0.919 |
| 10 | SRR1455698 | GTEX | — | 0.919 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 22 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| COAGULATION | 0.400 | Binimetinib | — uncovered |
| KRAS_SIGNALING_DN | 0.399 | Remibrutinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.317 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.240 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.239 | Idelalisib | — uncovered |
| MYOGENESIS | 0.230 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.228 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.221 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.167 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.164 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.152 | Temsirolimus | — uncovered |
| PANCREAS_BETA_CELLS | 0.145 | Cobimetinib | — uncovered |
| COMPLEMENT | 0.138 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.135 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.117 | Remibrutinib | — uncovered |
| APICAL_JUNCTION | 0.086 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.081 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.068 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.050 | Idelalisib | — uncovered |
| HYPOXIA | 0.049 | Idelalisib | — uncovered |